Recruiting
Phase 3

InfasurfAero™

Sponsor:

ONY

Code:

NCT05960929

Conditions

Respiratory Distress Syndrome (Neonatal)

Intubation Complication

Death; Neonatal

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Interventions

Infasurf Aero™

Study Details

Brief summary:

The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.

Conditions

Respiratory Distress Syndrome (Neonatal)

Intubation Complication

Death; Neonatal

Study ID

NCT05960929

Start date

Jan 1, 2025

Status verified date

Nov, 2024

Completion date

Apr 1, 2026

Anticipated

Primary completion date

Jan 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Inclusion Criteria:

Inclusion criteria include ALL of the following:

1. Written informed consent obtained by parent or legal representative prior to or after birth
2. Gestational age at birth ≥ 29 0/7 AND ≤ 35 6/7 weeks
3. Birthweight ≥ 1,000 AND ≤ 3,500 grams
4. Age ≥ 1 hour AND ≤ 6 hours
5. Clinical diagnosis of surfactant-deficient RDS, with EITHER i. a Silverman-Anderson Retraction Score ≥ 5 (in Room Air), OR ii. signs of respiratory distress (tachypnea, retractions, grunting) AND radiographic confirmation
6. Require CPAP
7. Respiratory Severity Score (RSS) ≥ 1.25 AND ≤ 2.4
8. If subject is >346/7 weeks' gestation a chest radiograph is required

Exclusion Criteria:

Exclusion criteria are ANY of the following:

1. Surfactant administration prior to randomization
2. Mechanical ventilation prior to randomization
3. Major congenital anomaly (suspected or confirmed)
4. Abnormality of the airway (suspected or confirmed)
5. Respiratory distress presumed secondary to an etiology other than RDS (e.g., suspected pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemia shock, hypoxic ischemic encephalopathy)
6. Apgar score < 3 at 5 minutes of age
7. Umbilical cord gas pH <7.0 or BD > 10
8. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk

Study Design

Enrollment

220 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment Arm

A single dose of Calfactant at 6ml/kg administered via the Infasurf Aero™ Nebulizer until completion.

sham comparator: Control Arm

Low flow respiratory air alone through the InfasurfAero™ Nebulizer until completion.

Interventions

Infasurf Aero™

A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.

Primary outcome measure

  • CPAP failure and or death [ Time Frame: Within 1st week of age ]

Central Contacts and Locations

Central contacts

Locations

St. Josephs Hospital and Medical Center

Recruiting

Phoenix, Arizona, United States, 85013

Contacts

Principal Investigator:

mohammed Elkhwad, MD

Phoenix Children's

Recruiting

Phoenix, Arizona, United States, 85016

Contacts

Principal Investigator:

Greg Martin, MD

Sharp Mary Birch Hospital for Women & Newborns

Recruiting

San Diego, California, United States, 92123

Contacts

Principal Investigator:

Anup Katheria, MD

University of Florida -Jacksonville

Recruiting

Jacksonville, Florida, United States, 32209

Contacts

Principal Investigator:

Henry Zapata Galarza, MD

Kapi'olani Medical Center for Women & Children

Recruiting

Honolulu, Hawaii, United States, 96826

Contacts

Principal Investigator:

Sheri Kuo, MD

Jersey Shore University Medical Center

Recruiting

Neptune, New Jersey, United States, 07753

Contacts

Principal Investigator:

Ann Ross, MD

Sisters of Charity Hospital

Recruiting

Buffalo, New York, United States, 14214

Contacts

George Albert, MD

716-862-1000

Principal Investigator:

George Albert, MD

Western TN- Jackson-Madison County General Hospital

Recruiting

Jackson, Tennessee, United States, 38301

Contacts

Principal Investigator:

Stacy Slagle, MD

Utah Valley Hospital

Recruiting

Provo, Utah, United States, 84604

Contacts

Principal Investigator:

Steven Minton, MD

Unity Point Meriter

Recruiting

Madison, Wisconsin, United States, 53715

Contacts

Shayla Schwingle Study Coordinator

(608) 417-6000snschwingle@wisc.edu

Principal Investigator:

Dinushuan Kaluarachchi, MD

More Information

Sponsor

ONY

Last update posted

Mar 30, 2025

Last verified

Nov, 2024

Keywords

  • Infasurf
  • Calfactant
  • Inhalation
  • Nebulization
  • Preterm
  • InfasurfAero
  • Respiratory Distress Syndrome
  • Neonatal
  • NICU
  • CPAP
  • Intubation
  • Aerosol
  • CPAP Failure

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by ONY on 2025-03-30.